Skip to main content
I.Ceram logo

I.Ceram — Investor Relations & Filings

Ticker · ALICR ISIN · FR0011511971 LEI · 969500R28RHD3HDEIL86 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2024-11-27 Legal Proceedings Report
Country FR France
Listing PA ALICR

About I.Ceram

https://www.iceram.fr/

I.Ceram specializes in the design, manufacture, and marketing of orthopedic and reconstructive implants. The company's core technology is centered on porous alumina bioceramics, though it also utilizes metals and polymers. A key innovation is the development of active implants, such as its Ceramil line, which can be loaded with antibiotics like gentamicin. This feature enables the localized delivery of medication directly to bone tissue to prevent and treat infections post-surgery. The product portfolio includes implants for various joints and a bioceramic sternal implant designed for reconstructive procedures.

Recent filings

Filing Released Lang Actions
I.CERAM - Liquidation Judiciaire avec poursuite d'activité jusqu'au 06 décembre - Suspension du cours de Bourse
Legal Proceedings Report Classification · 1% confidence The document announces a significant legal and operational event: the conversion of a 'redressement judiciaire' (reorganization/receivership) into 'liquidation judiciaire' (judicial liquidation) with continued activity until a specific date. It also mentions the suspension of the stock price. This type of announcement, detailing legal proceedings, court judgments, and their immediate impact on the company's status, fits best under the 'Legal Proceedings Report' (LTR) category, as it is a direct update on a significant legal matter involving the company's solvency and operations. It is not a standard financial report (10-K, IR, ER) nor a management change (MANG) or financing event (CAP). Given the nature of the announcement, LTR is the most appropriate classification.
2024-11-27 French
I.CERAM - Professor Pascal Leprince, Head of the Cardiac Surgery Department at the Pitié-Salpêtrière Hospital in Paris, has agreed to set up a pilot clinical
Regulatory Filings Classification · 1% confidence The document announces an agreement to set up a pilot clinical study for an antibiotic-loaded Porous Ceramic Sternal Stabilisation Implant (ISS.C) involving a hospital department and the company I.CERAM. It details the purpose, objectives, and significance of this medical/technological development, including quotes from the involved surgeon. This content is characteristic of a press release or a specific announcement regarding a new development, partnership, or clinical trial initiation, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory filing (RNS). Since there is no specific category for 'Clinical Study Announcement' or 'Product Development Update', and it is not a standard financial report, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-financial, official company announcement, or potentially 'LTR' if it were related to legal proceedings, which it is not. Given the nature of the announcement (a partnership for a clinical study), RNS is the most appropriate fallback for a specific corporate update that doesn't match the other defined categories.
2024-11-07 English
I.CERAM - Le Professeur Pascal Leprince, Chef du service de chirurgie cardiaque de l’hôpital de la Pitié-Salpêtrière à Paris, donne son accord pour la mise en place d’une étude clinique pilote
Regulatory Filings Classification · 1% confidence The document announces a significant development for the company I.CERAM: the agreement to launch a pilot clinical study for their novel antibiotic-loaded porous ceramic sternal stabilization implant (ISS.C) at the Pitié-Salpêtrière hospital, led by Professor Pascal Leprince. This is a strategic announcement detailing a new clinical trial phase and providing context on the medical need and the company's technology. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is a specific announcement related to product development and clinical progress, which often falls under general investor relations or regulatory updates. Given the options, this type of announcement about a new clinical study initiation, especially one involving a specific medical device and expert opinion, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but since it reads like a press release announcing a step forward, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, as there is no specific code for 'Clinical Trial Initiation Announcement'. It is not a Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV). Since it is a detailed announcement about a specific business/product development step, RNS is the best fit among the provided codes for a non-financial, non-management change announcement.
2024-11-07 French
I.CERAM - Résultat du 1er semestre 2024
Interim / Quarterly Report Classification · 1% confidence The document provides a summary of the company's financial performance for the first half of 2024 (S1-2024), including a table of key financial data (revenue, operating result, net result) and a management commentary explaining the results. Although it mentions that the full report is available on the website, the document itself contains substantive financial data and analysis for an interim period, which qualifies it as an Interim/Quarterly Report (IR) rather than just an announcement. H1 2024
2024-10-31 French
I.CERAM - Assemblée générale mixte du 26 septembre 2024 - Mise à disposition des documents préparatoires
AGM Information Classification · 1% confidence The document explicitly announces a 'Assemblée générale mixte' (Combined General Meeting) scheduled for September 26, 2024. It details the publication of the notice of meeting ('avis de réunion valant avis de convocation') in official bulletins (BALO) and newspapers, and directs shareholders to where preparatory documents can be consulted. This content directly relates to the materials and announcements surrounding the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (2184 chars) is short, but the content is the announcement/information package for the AGM itself, not just a notice that a report is available, making AGM-R more specific than RPA or RNS.
2024-09-11 French
I.CERAM - Comptes définitifs de l’exercice 2023 & Mise à disposition du Document d’Enregistrement Universel
Report Publication Announcement Classification · 1% confidence The document is titled "Comptes définitifs de l'exercice 2023 Mise à disposition du Document d'Enregistrement Universel" (Final accounts for the 2023 financial year Availability of the Universal Registration Document). It presents the definitive financial data for 2023, including revenue, gross margin, and net result, and mentions that the Board approved the final accounts and the Universal Registration Document (DEU). The text explicitly states that the DEU 2023, which includes the annual report (rapport annuel 2023), management report (rapport de gestion), statutory accounts (comptes sociaux), and the auditor's report (rapport du commissaire aux comptes), has been filed with the AMF (Autorité des Marchés Financiers) and made available to the public. The document itself contains the key financial highlights and context, resembling an Earnings Release (ER) or a summary preceding the full Annual Report. However, the core purpose of this specific communication is the *announcement* of the availability of the comprehensive Universal Registration Document (DEU), which encompasses the Annual Report (10-K equivalent in France) and the Auditor's Report (AR). Since the document is a press release announcing the filing and availability of the DEU, and it contains the key financial figures (similar to an ER), we must choose the most appropriate category. The DEU filing in France typically combines the Annual Report (10-K) and Governance/Audit information. Given the explicit mention of the 'Document d'enregistrement universel' being made available, and the inclusion of the 'rapport annuel 2023' and 'rapport du commissaire aux comptes', this is strongly related to the Annual Report cycle. If the document were the full, detailed 10-K, it would be classified as 10-K. If it were just the initial results announcement, it would be ER. Since it is an announcement confirming the finalization and availability of the comprehensive annual filing package (DEU), which includes the annual report and audit report, the most fitting category that covers the publication announcement of major annual filings, especially when it contains the key financial summary, is often the Earnings Release (ER) if it focuses on results, or RPA if it strictly focuses on the publication announcement. Given the structure—presenting the final results table and then announcing the availability of the full DEU (which contains the 10-K/AR components)—it functions primarily as the official release of the annual financial results, even if it's slightly later than a typical ER due to the judicial situation. The presence of the final accounts and the auditor's report context points towards the annual reporting cycle. Considering the definitions: - 10-K: Official yearly report (This document announces it, but isn't the full report itself). - AR: Standalone audit reports (The audit report is *part* of the DEU being announced). - ER: Initial announcement of periodical financial results (This is the *definitive* result announcement). - RPA: Announcement regarding the timing, release, or publication of company reports. The document is a press release announcing the finalization of the 2023 accounts and the availability of the DEU. This aligns perfectly with the definition of a Report Publication Announcement (RPA), as it is announcing the release of the comprehensive annual filing. Confidence is high because the text explicitly states the 'Mise à disposition du Document d'Enregistrement Universel' (Announcement of availability of the URD).
2024-08-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.